Brown Financial Advisors Has $434,000 Holdings in Kenvue Inc. (NYSE:KVUE)

Brown Financial Advisors lowered its stake in shares of Kenvue Inc. (NYSE:KVUE) by 16.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 20,316 shares of the company’s stock after selling 4,036 shares during the period. Brown Financial Advisors’ holdings in Kenvue were worth $434,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in KVUE. AMF Tjanstepension AB boosted its position in shares of Kenvue by 187.3% during the third quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock valued at $2,787,000 after buying an additional 78,540 shares during the last quarter. Signaturefd LLC lifted its stake in Kenvue by 394.0% during the 3rd quarter. Signaturefd LLC now owns 4,061 shares of the company’s stock valued at $94,000 after acquiring an additional 3,239 shares in the last quarter. International Assets Investment Management LLC boosted its holdings in Kenvue by 1,529.5% during the 3rd quarter. International Assets Investment Management LLC now owns 106,341 shares of the company’s stock worth $2,460,000 after acquiring an additional 99,815 shares during the last quarter. Allworth Financial LP grew its stake in shares of Kenvue by 5.9% in the 3rd quarter. Allworth Financial LP now owns 20,023 shares of the company’s stock worth $463,000 after acquiring an additional 1,113 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Kenvue by 143.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 293,310 shares of the company’s stock worth $6,822,000 after acquiring an additional 172,596 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on KVUE shares. Citigroup cut their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Canaccord Genuity Group reduced their target price on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a report on Friday, February 7th. Piper Sandler lifted their price target on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a report on Monday. Barclays reduced their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday, January 17th. Finally, Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $23.08.

Kenvue Price Performance

KVUE opened at $23.33 on Tuesday. The firm has a 50-day moving average price of $21.33 and a 200-day moving average price of $22.21. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $44.72 billion, a price-to-earnings ratio of 44.01, a PEG ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.52%. Kenvue’s payout ratio is 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.